Alerts

Call for Abstracts "Gut-Retina Axis"

Microbiota 2022 ADS Call for abstract v2

A new hot topic will be introduced in Targeting Microbiota 2022  "The Gut-Retina Axis". You can submit abstracts of your latest research on this interesting relationship between the gut microbiota and the retina "Gut-Retina axis". 

Find more details about the abstract submission procedure here.

Other Topics.


Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

May the Microbiota of the long-lived Naked Mole-rat Effect Human Health?

Microbiota 2022 Speaker Prof. Dr. med. Gerd Birkenmeier

Porf.  Gerd Birkenmeier from University of Leipzig, Germany will join the Targeting Microbiota 2022 Congress and give a presentation entitled "May the Microbiota of the long-lived Naked Mole-rat Effect Human Health?.

Join Prof. Birkenmeier in Targeting Microbiota 2022 to benefit from his experience on the host - microbiota interactions.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Targeting Microbiota 2022 Highlights

WhatsApp Image 2022 07 28 at 4.58.41 PM

The 9th ISM Annual Meeting will take place from the 19th to the 21st of October in Paris, France and Online. More than 300 participants from 25 different countries will be attending, and more than 86 communications will be presented this year.

Dr. Marvin Edeas, Founder & Chairman of ISM, Institut Cochin, INSERM, Université de Paris, France, stated: “We will be back this year in person in Paris after 2 years, with more diversity of topics which may explain the complexity of our microbiota”.

Dr. Edeas thinks that we are still at the beginning in our exploration and we probably need to desiccate more the mechanism behind microbiota efficacy such as: extracellular vesicles and exosomes and their impact on microbiota communication and microbiota-host relationship, along with their potential implication in disease. Further explore the role of microbiota and its metabolites on iron metabolism should be highlighted.

Targeting Microbiota 2022 will highlight many new topics: Oral microbiota, vaginal microbiota, skin microbiota, metabolites, microbiota biofilms, retinal disorders, respiratory infections, arterial thrombosis, ischemic stroke, ageing, circadian system, depression, FMT, multi-omics, gene editing, precision medicine, cancer immunotherapy, mineral water, Mediterranean diet, weight loss...

Abstract Submission

  • Short Oral Presentation submission deadline: September 30
  • Poster Presentation submission deadline: October 7

More details on abstract submission

Registration

You can choose whether to register for in-person or online participation. Registration details.

If you need more information don't hesitate to contact us.

Interactions of Skin Microbiota with Chosen Plant Extracts and Natural Products

Microbiota 2022 Speakers 11Dr. Sebastian Granica, Medical University of Warsaw, Poland, will be joining the 9th ISM Annual Meeting to discuss the "Interactions of Skin Microbiota with Chosen Plant Extracts and Natural Products". 

Join Targeting Microbiota 2022 to lear more about the skin microbiota. Secure a place.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Gut Microbiome and Retinal Disorders: Recent Advances and Perspectives

Microbiota 2022 Speakers 9Dr. Dimitra Skondra, University of Chicago, USA, will be joining the 9th ISM Annual Meeting to discuss "Gut Microbiome and Retinal Disorders: Recent Advances and Perspectives".

Recent work demonstrates important role of gut microbiome and retinal diseases such as age-related macular degeneration and retinopathy of prematurity. Emerging evidence for the existence and pathways of gut-retina axis can elucidate previously unknown pathways involved in retinal diseases and also presents an exciting potential therapeutic avenue. This talk aims to provide an update on recent advances in the current knowledge on the relationship between the gut microbiome and retinal disorders.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

 

Vaginal Microbiota and Dysbiosis: Recent Advances and Perspective

Microbiota 2022 Speakers Gary VentoliniProf. Gary Ventolini, Texas Tech University Health Sciences Center, USA, will be joining the 9th ISM Annual Meeting to discuss the Recent Advances and Perspectives on Vaginal Microbiota and Dysbiosis. 

Trillions of bacteria colonize the human body and 9% are found in the female genital tract: vulva, vagina, cervix/uterus and adnexa. Vaginal microbiota influence from conception to birth has only been unbent during the last decade.

This presentation will appraise the vaginal microbiota, will review changes taking place during dysbiosis, and will update on current advances and outlooks regarding the impact on human reproduction. 

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbiota & Microbiotal Medicine: Where We are Now & What’s Next?

Microbiota 2022 Speakers 1

Dr. Marvin Edeas, Founder & Chairman of ISM, Institut Cochin, INSERM, Université de Paris, France, will introduce the 9th Targeting Microbiota meeting and he will talk about "Microbiota & Microbiotal Medicine: Where We are Now & What’s Next?".

The aim of Dr. Marvin Edeas is to introduce a new way of thinking about the medicine of tomorrow. He will initiate the reflection and discussion about strategies which will allow us to accelerate Microbiotal medicine.

Dr. Marvin Edeas will try to discuss:

- Why we failed to treat many diseases?

- Do we need to dedicate a specific treatment to one specific organ or specific pathology?

Dr. Marvin Edeas believes that the medicine of tomorrow will connect all organs together and with our microbiota and microbiome. All therapeutic strategies will come through the way we will take into consideration the quality of Microbiota and metabolites, signaling pathways, epigenetic and more.

Dr. Edeas thinks that we are still at the beginning in our exploration and we probably need to desiccate more the mechanism behind microbiota efficacy such as: extracellular vesicles and exosomes and their impact on microbiota communication and microbiota-host relationship, along with their potential implication in disease. Further explore the role of microbiota and its metabolites on iron metabolism should be highlighted.

He will discuss the 4 main axes that should be exploreed in the furture:

  1. Olfactory receptors;
  2. Brain and behaviour;
  3. Ageing & longevity;
  4. Artificial intelligence and algorithms.

 

Reference: Microbiota medicine: towards clinical revolution - BMC Journal of Translational Medicine

Join Targeting Microbiota 2022 to learn more about the future of microbiotal medicine.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Gene Editing and Microbiome Therapy

Nahla MansourProf. Nahla Mansour, National Research Center, Egypt, will be joining us this October to discuss her latest findings on "Gene Editing and Microbiome Therapy". 

Gene editing holds a promising future in microbiome therapy and exploring the complex interplay between members of the microbiome and our bodies. 

In this presentation, Dr. Mansour will highlight the re-emerging of gene editing tools and multiple strategies in microbiome therapy past, present, and future. 

She will show her previous work describing the genetically engineered probiotic strains that have been constructed by our group and also our new project using CRISPR- Cas tools.

A whole session will be dedicated to the Strategies, Innovations & Challenges to Target Microbiota Dysbiosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

A Gut Commensal, Parabacteroides distasonis, and Type 1 Diabetes Onset

Targeting Microbiota 2022 Emrah AltindisDr. Emrah Altindis, from the Biology Department Boston College, USA, will be joining us this October to discuss his latest findings on the "A Gut Commensal, Parabacteroides distasonis, and Type 1 Diabetes Onset". 

Type 1 Diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic β-cells. One of the earliest aspects of this process is development of autoantibodies and T-cells directed at an epitope in the B-chain of insulin (insB:9-23). Analysis of microbial protein sequences with homology to insB:9-23 sequence revealed 17 peptides showing >50% identity to insB:9-23. Of these, one peptide, found in the normal human gut commensal Parabacteroides distasonis, activated both human T cell clones from T1D patients and T-cell hybridomas from non-obese diabetic (NOD) mice specific to insB:9-23. Immunization of NOD mice with P. distasonis insB:9-23 peptide mimic or insB:9-23 peptide verified immune cross-reactivity. Colonization of female NOD mice with P. distasonis accelerated the development of T1D, increasing macrophages, dendritic cells and destructive CD8+ T-cells, while decreasing FoxP3+ regulatory T-cells. Western blot analysis identified P. distasonis reacting antibodies in sera of NOD mice colonized with P. distasonis and human T1D patients. Furthermore, adoptive transfer of splenocytes from P. distasonis treated mice to NOD/SCID mice enhanced disease phenotype in the recipients. Finally, analysis of human infant gut microbiome data revealed that exposure of infants to P. distasonis may modulate disease pathogenesis. Taken together, these data demonstrate the potential role for an insB:9-23-mimimetic peptide from gut microbiota as a molecular trigger or modifier of T1D pathogenesis.

Join Dr. Altindis in Targeting Microbiota 2022 to benefit from his experience and better understand the relationship between gut commensals and diabetes onset.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Influence of the Gut Microbiome in Ischemic Stroke Risk and Ischemic Stroke Outcome

Microbiota 2022 Speakers Miquel LledósDr. Miquel Lledós from the Biomedical Research Institute Sant Pau, Spain will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Influence of the Gut Microbiome in Ischemic Stroke Risk and Ischemic Stroke Outcome".

We performed shotgun metagenomics sequencing to analyse the taxonomic profiles in ischemic stroke patients. We aimed to identify microbiota taxa associated with: risk of ischemic stroke, neurological outcome in the acute phase at 6h and 24h (classified with the National Institute of Health Stroke Scale (NIHSS) as mild, moderate or severe stroke), and functional outcome at 3 months measured with the modified Rankin Scale (mRS). We found multiple new taxonomic profiles associated with stroke, revealing that gut microbiome could be an important factor associated with stroke risk and stroke acute and long-term outcome.

Join Dr. Lledós in Targeting Microbiota 2022 to benefit from his experience and expand your knowledge about the link between the microbiota and stroke.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Interactions Between Epithelial Proteases And Gut Microbiota Biofilms During Intestinal Disease

Jean Paul Motta Microbiota 2022 Speakers 15Dr. Jean-Paul Motta, Institute of Digestive Health Research, France, will join Targeting Microbiota this October to present his new studies on the "Interactions Between Epithelial Proteases And Gut Microbiota Biofilms During Intestinal Disease". 

Dr. Motta states that Inflammatory Bowel Disease (IBD) is linked with abnormal upregulation of epithelial protease, such as elastase and thrombin. Their recent works aim to decipher the mechanisms by which such high protease activity could fuel intestinal inflammation via an action on host receptors, but also to directly alter commensal microbiota forming biofilms at the mucosal surface. 

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Host / Microbiota Interaction at the Mucosal Surface – Importance of a No Man’s Land !

Dr. Benoit ChassaingDr. Benoit Chassaing from Institut Cochin, France will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Host / Microbiota Interaction at the Mucosal Surface – Importance of a No Man’s Land !".

Recent researches have highlighted the importance of a proper host-microbiota interaction at the mucosal surface, with the observation of microbiota encroachment within the normally sterile mucus layer in preclinical models of chronic inflammatory diseases as well as in humans suffering IBD or type 2 diabetes.

Dr. Chassaing's presentation will discuss dietary factors involved in the promotion of microbiota encroachment, as well as mechanisms by which targeted immunization can be used to prevent / reverse encroachment and hence protect against chronic inflammatory diseases.

Join Dr. Chassaing in Targeting Microbiota 2022 to benefit from his experience on the host - microbiota interactions.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Fecal Microbiota Transplantation as an Immunomodulatory and Anti-Infective Agent

Microbiota 2022 Congress speaker Jarosław BilinskDr. Jarosław Biliński, from Medical University of Warsaw, Poland will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Fecal Microbiota Transplantation as an Immunomodulatory and Anti-Infective Agent".

There is mounting evidence that the gut microbiome directly influences immune responses, especially in patients with hematological malignancies undergoing hematopoietic cell transplantation. Recent studies show that fecal microbiota transplantation could decrease the number of infectious complications, decolonize the gut from antibiotic-resistant bacteria and even treat immune complications like graft-versus-host disease. More attention is paid to the prophylactic use of microbiota modulation in most affected patients, which could revolutionize current practices.

Join Dr. Biliński in Targeting Microbiota 2022 to benefit from his experience and better understand microbiota immunotherapy.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Cancer therapy and Microbiota

Microbiota 2022 Congress speaker Maria Cecilia GironDr. Maria Cecilia Giron, from University of Padova, Italy will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Cancer therapy and Microbiota".

Join Dr. Giron in Targeting Microbiota 2022 to benefit from his experience and better understand the role of microbiota in arterial thrombosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Host-Microbes Mechanisms during E. coli Infections and Diet-induced Dysmetabolism

Microbiota 2022 Speakers

Dr. Matteo Serino, CRCN researcher from INSERM (France), will be joining us this October to present a talk entitled "Host-Microbes Mechanisms during E. coli Infections and Diet-induced Dysmetabolism".

A high-fat diet-induced gut microbiota dysbiosis is at the carrefour between E. coli infections and metabolic diseases such as obesity and type 2 diabetes. Dr. Serino will discuss about both cellular and molecular mechanisms governing dysbiosis-induced systemic, gut and hepatic inflammation in lean and obese mice.

These mechanisms include: i) platelets modulation as sentinels of E. coli-induced systemic inflammation; ii) NLRP3 inflammasome activation to control gut inflammation and iii) modulation of hepatic microRNAs as bridge molecules between gut microbes and hepatic inflammation.

Join us in Targeting Microbiota 2022 and benefit from the experience of Dr. Serino. Don't forget that you can share your work in this session by submitting your abstract.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbial Biomarkers to Predict Respiratory Infection

Microbiota 2022 Congress speaker Claire Woodal

Dr. Claire Woodall, a Daphne Jackson Fellow at the University of Bristol, will be presenting her research at the 9th ISM Annual Meeting to discuss “Microbial Biomarkers to Predict Respiratory Infection”.

Respiratory tract infections are the most common infections seen in primary care, and the single greatest contributor to the overall burden of infections worldwide. Community-acquired viral respiratory infection includes influenza-like illness and more recently, COVID-19 disease. Even in otherwise healthy adults, respiratory infections are common and they may experience multiple infections per year.

Microbial biomarker studies are proposed as an emerging tool to identify healthy adults most susceptible to respiratory infection. If this identification were possible, then alongside clinical primary care standard practice protective measures can be implemented early. This talk discusses the current evidence for microbial biomarkers predicting susceptibility to respiratory infection and asks the question: is the science there yet?

Join us in Targeting Microbiota 2022 and benefit from the experience of Dr. Woodall. Don't forget that you can share your work in this session by submitting your abstract.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbiota and Drug Metabolism: Towards a Personalized Medicine

Microbiota 2022 Dr. Cristina Giaron 2Dr. Cristina Giaroni from University of Insubria, Italy will be joining us this October to moderate a session entitled "Microbiota and Drug Metabolism: Towards a Personalized Medicine". 

The gut microbiota plays a pivotal role in human health by modulating gut epithelial and immune cell functions, preventing pathogen colonization, and providing essential nutrients and bioactive metabolites. From a metabolic standpoint, gut microbes actively participate to drug metabolism, influencing drug disposition, half-life, and efficacy. Gut bacteria are not only a major source for local drug metabolism but can also indirectly affect xenobiotic stability by modulating host-mediated metabolic clearance as well as by competition of bacterial-derived metabolites for host drug metabolic pathways.

In view of the existing bidirectional drug-microbiota relationship, drugs themselves can influence the composition and function of the gut microbiota. In this context, alterations of the gut microbiota homeostasis after broad spectrum antibiotic administration does not only deprive the host from essential bacterial metabolites but may also profoundly alter drug metabolic pathways. A further critical issue is the development of antibiotic resistance in some species of bacteria. The human gut is considered the main reservoir of antibiotic resistance genes. Antibiotic treatment may rapidly increase the pool of resistance genes, favouring the formation of a biofilm rich of microorganisms resistant against several antibiotics thus contributing to reduce host defence and hampering the efficacy of treatments for bacterial infections.

Overall, these considerations open a new avenue for a research aiming at evaluating the relevance of drug-gut microbiota interplay in the variation of individual responses to disease treatment, thus opening the possibility for more personalized therapeutic approaches.

Join us in Targeting Microbiota 2022 and benefit from the experience of Dr. Giaroni. Don't forget that you can share you work in this session by submitting your abstract.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

 

Role of the Gut Microbiota in Arterial Thrombosis

Microbiota 2022 Dr. Christoph ReinhardtDr. Christoph Reinhardt, from University Mainz, Germany, will be joining us this October to discuss his latest findings on the "Role of the Gut Microbiota in Arterial Thrombosis". 

The gut microbiota impacts vascular phenotypes in the small intestinal mucosa but via the gut-liver axis also acts remotely on the hepatic sinusoidal endothelium.

Experimentation with germ-free mouse models indicates that this densely colonized microbial ecosystem promotes vascular inflammation and interferes with the atherosclerotic lesion development. Importantly, involving endothelial and platelet-dependent mechanisms, the gut microbiota promotes arterial thrombus growth.   

Join Dr. Christoph Reinhardt in Targeting Microbiota 2022 to benefit from his experience and better understand the role of microbiota in arterial thrombosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Oral Microbial Dysbiosis and Oral Diseases

Microbiota 2022 Dr. Xin XuDr. Xin Xu, from Sichuan University, China, will be joining us this October to discuss his latest findings on "Oral Microbial Dysbiosis and Oral Diseases". 

Dr. Xu's talk will discuss the microbial baseline in oral health, and oral diseases that are associated with microbial dysbiosis. Eocological approaches that aims to restore microbial ecology and thus rescue oral diseases will also be discussed.

Book your spot for Targeting Microbiota 2022 to benefit from Dr. Xu's experience and boost your knowledge on the oral microbiota.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Probiotics and FMT as Add-On Therapies for Depression

Dr André SchmidtDr. André Schmidt, from the University of Basel, Switzerland, will be joining us in October to discuss his latest findings on "Probiotics and FMT as Add-on Therapies for Depression". 

In fact, depression is a highly prevalent and burdensome psychiatric disorder. Even though antidepressants and further therapeutic approaches are widely applied, up to 30% of treatment-resistant patients experience residual symptoms when receiving optimized treatments. Therefore, the development of novel and more efficient treatment approaches is urgently needed. Compelling evidence shows that alterations in the gut microbiota composition impact human physiology and contribute to diseases including psychiatric disorders like depression. The manipulation of the gut microbiota as part of the microbiota-gut-brain (MGB) axis has emerged as promising new target for the treatment of depression.

In this talk, Dr. Schmidt presents data from a randomized controlled trial exploring clinical and biological effects along the MGB axis of probiotic supplementation in patients with depression. He further shows data from two depressed patients receiving fecal microbiota transplantation. These findings will be discussed in the view of current research and potential suggestions for future studies will be proposed aiming at developing microbial interventions for depression care.

Join Dr. Schmidt and other experts to know more about the "Strategies, Innovations & Challenges to Target Microbiota Dysbiosis".

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

The Probiotic Strain H. alvei HA4597 for Weight Loss

Dr Pierre DéchelotteIt is a great pleasure to welcome Dr. Pierre Déchelotte, from Rouen Normandy University, France during the 9th World Congress.

Dr. Déchelotte will present his most recent findings on The Probiotic Strain H. alvei HA4597 for Weight Loss, during the session dedicated to "Strategies, Innovations & Challenges to Target Microbiota Dysbiosis"

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next